Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Director | April 28, 2011 | April 28, 2011 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date April 28, 2011 · Filed April 28, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,679 |
Reported balance
After 2011-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2011-04-28 · Grant · Acquired 5,500 · Balance 97,679 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby SLAT | 5,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,162 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,162 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001174475-26-000002 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001174475-26-000002 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000003 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000003 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,535 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001968202-24-000102 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,535 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,535 | $1,040.00 | $1,596,400.00 |
DisclosureSEC source: 0001968202-24-000102 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,535 | $625.60 | $960,296.00 |
DisclosureSEC source: 0001968202-24-000102 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,172 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001104659-24-066045 · tm2414958-1_4seq1.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,535 Underlying: Common Stock · 1,172 shares Expires 2032-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,172 | $974.86 | $1,142,535.92 |
DisclosureSEC source: 0001104659-24-066045 · tm2414958-1_4seq1.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,172 | $625.60 | $733,203.20 |
DisclosureSEC source: 0001104659-24-066045 · tm2414958-1_4seq1.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000022 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000022 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,049 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001883850-23-000109 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,049 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,049 | $898.00 | $1,840,002.00 |
DisclosureSEC source: 0001883850-23-000109 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,049 | $482.68 | $989,011.32 |
DisclosureSEC source: 0001883850-23-000109 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,070 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001968202-23-000009 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,070 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 22, 2023. F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,070 | $798.42 | $2,451,149.40 |
DisclosureSEC source: 0001968202-23-000009 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 22, 2023. Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,070 | $520.01 | $1,596,430.70 |
DisclosureSEC source: 0001968202-23-000009 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 22, 2023. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,071 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001883850-23-000045 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,070 Underlying: Common Stock · 3,071 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $797.00 | $398,500.00 |
DisclosureSEC source: 0001883850-23-000045 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,162 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,071 | $798.00 | $2,450,658.00 |
DisclosureSEC source: 0001883850-23-000045 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,071 | $520.01 | $1,596,950.71 |
DisclosureSEC source: 0001883850-23-000045 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001883850-23-000027 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,141 Underlying: Common Stock · 1 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $747.00 | $747.00 |
DisclosureSEC source: 0001883850-23-000027 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1 | $520.01 | $520.01 |
DisclosureSEC source: 0001883850-23-000027 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,070 | $0.00 Strike: $520.01 | $0.00 |
DisclosureSEC source: 0001883850-23-000025 · edgardoc.xml · derivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,142 Underlying: Common Stock · 3,070 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,070 | $747.14 | $2,293,719.80 |
DisclosureSEC source: 0001883850-23-000025 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 3,070 shares of Company stock on January 6, 2023 at prices ranging from $747.00 to $747.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 6, 2023 at each separate price. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,070 | $520.01 | $1,596,430.70 |
DisclosureSEC source: 0001883850-23-000025 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000019 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000019 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,564 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · derivative · entry 19 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,049 Underlying: Common Stock · 1,564 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,431 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · derivative · entry 18 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,431 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $748.49 | $374,245.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 16 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $768.11 | $153,622.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 15 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2022 at prices ranging from $768.08 to $768.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 201 | $767.25 | $154,217.25 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 14 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 201 shares of Company stock on November 8, 2022 at prices ranging from $767.09 to $767.36. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 201 | $766.74 | $154,114.74 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 13 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 201 shares of Company stock on November 8, 2022 at prices ranging from $766.59 to $766.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $765.19 | $76,519.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 12 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $764.23 | $152,846.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 11 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,784 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2022 at prices ranging from $764.10 to $764.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $763.19 | $152,638.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 10 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,984 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2022 at prices ranging from $763.18 to $763.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $761.53 | $76,153.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 9 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,184 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $760.70 | $152,140.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,284 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2022 at prices ranging from $760.50 to $760.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $754.70 | $150,940.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on November 8, 2022 at prices ranging from $754.68 to $754.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $753.66 | $226,098.00 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on November 8, 2022 at prices ranging from $753.15 to $753.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 203 | $752.14 | $152,684.42 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 203 shares of Company stock on November 8, 2022 at prices ranging from $752.02 to $752.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 126 | $751.23 | $94,654.98 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 126 shares of Company stock on November 8, 2022 at prices ranging from $751.10 to $751.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,564 | $482.68 | $754,911.52 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,764 | $748.48 | $1,320,318.72 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,749 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,764 shares of Company stock on November 8, 2022 at prices ranging from $748.24 to $748.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2022 at each separate price. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,431 | $374.12 | $909,485.72 |
DisclosureSEC source: 0001883850-22-000094 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 408 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · derivative · entry 8 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,431 Underlying: Common Stock · 408 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 408 | $699.00 | $285,192.00 |
DisclosureSEC source: 0001708138-22-000030 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.